PROF PROFOUND MED CORP revenue, earnings and financials
For the quarter ended June 30, 2026, PROFOUND MED CORP reported revenue of $2.48M (up 12.3% from a year earlier), net income of −$9.54M and diluted EPS of −$0.26; over the last four quarters revenue was $19.1M and net income −$32.7M; for the fiscal year ended December 2025 revenue was $16.1M, up 50.7% on the year before.
PROF annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $16.1M, gross profit $11.4M, operating income −$41.3M, net income −$42.6M (margin -264.4%), EPS $1.41
- Fiscal year ended Dec 2024: revenue $10.7M, gross profit $7.04M, operating income −$33.1M, net income −$27.8M (margin -260.4%), EPS $1.12
- Fiscal year ended Dec 2023: revenue $7.20M, gross profit $4.31M, operating income −$28.7M, net income −$28.3M (margin -393.4%), EPS $1.34
PROF quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.48M (up 12.3% year over year), net income −$9.54M, EPS −$0.26
- Quarter ended Mar 31, 2026: revenue $5.34M (up 103.6% year over year), net income −$7.05M, EPS $0.19
- Quarter ended Dec 31, 2025 (from the annual report): revenue $5.98M (up 43.1% year over year), net income −$8.17M, EPS $1.31
- Quarter ended Sep 30, 2025: revenue $5.29M (up 86.8% year over year), net income −$7.98M, EPS $0.26
- Quarter ended Jun 30, 2025: revenue $2.21M (down 1.0% year over year), net income −$15.7M, EPS −$0.52
- Quarter ended Mar 31, 2025: revenue $2.62M (up 82.1% year over year), net income −$10.7M, EPS $0.36
- Quarter ended Dec 31, 2024 (from the annual report): revenue $4.18M, net income −$4.95M, EPS $0.19
- Quarter ended Sep 30, 2024: revenue $2.83M, net income −$9.37M, EPS $0.38
- Quarter ended Jun 30, 2024: revenue $2.23M, net income −$6.92M, EPS $0.28
- Quarter ended Mar 31, 2024: revenue $1.44M, net income −$6.59M, EPS $0.27
PROF cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$38.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$22.6M, share buybacks n/a
PROF balance sheet
- Jun 30, 2026: cash $38.3M, total assets $62.4M, total liabilities $12.6M, shareholders' equity $49.8M
- Mar 31, 2026: cash $50.3M, total assets $73.5M, total liabilities $14.0M, shareholders' equity $59.4M
- Dec 31, 2025: cash $59.7M, total assets $77.5M, total liabilities $11.0M, shareholders' equity $66.4M, long-term debt $4.50M
- Sep 30, 2025: cash $24.8M, total assets $42.3M, total liabilities $10.2M, shareholders' equity $32.1M
- Jun 30, 2025: cash $35.2M, total assets $49.7M, total liabilities $10.4M, shareholders' equity $39.3M, long-term debt $4.46M
- Mar 31, 2025: cash $46.4M, total assets $60.9M, total liabilities $10.1M, shareholders' equity $50.8M, long-term debt $4.49M
- Dec 31, 2024: cash $54.9M, total assets $70.2M, total liabilities $9.81M, shareholders' equity $60.4M, long-term debt $2.92M
- Dec 31, 2023: cash $26.2M, total assets $44.0M, total liabilities $12.7M, shareholders' equity $31.2M, long-term debt $5.00M
What is PROF's revenue?
PROFOUND MED CORP reported $19.1M of revenue over its last four quarters, through June 30, 2026.
Is PROF profitable?
No. PROFOUND MED CORP lost $32.7M over the last four quarters.
What is PROF's EPS?
Diluted earnings per share over the last four quarters were $1.50; −$0.26 in the latest quarter.